Observational studyEuropean journal of medical research2025
The role of serum acsl4 in differentiating early-stage breast cancer.
Observational study in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment.Experimental hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the serum levels and clinical significance of Acyl-CoA synthetase long-chain family member 4 (ACSL4) in patients with early-stage breast cancer, and to evaluate its potential as a diagnostic and prognostic biomarker.
methodsIn this prospective observational study, serum levels of ACSL4, inflammatory factors (CRP, IL-6, and IL-17), and tumor markers (CEA and CA153) were measured using enzyme-linked immunosorbent assay (ELISA) in 138 early-stage breast cancer patients and 115 patients with benign breast lesions. Demographic, clinical, and follow-up data were collected, and statistical analyses were performed to assess the diagnostic and prognostic value of ACSL4.
resultsSerum ACSL4 levels were significantly lower in early-stage breast cancer patients compared to those with benign breast lesions (p < 0.01). Serum ACSL4 levels showed diagnostic performance for early-stage breast cancer, with an AUC of 0.774 (95% CI 0.717-0.813), a cut-off value of 21.47 ng/ml, yielding 73.9% sensitivity and 65.2%. Although not statistically significant, trends in survival analysis suggested that lower ACSL4 levels might be associated with poorer outcomes. Multivariate logistic regression identified serum ACSL4 as an independent risk factor for early-stage breast cancer progression (OR 1.407, 95% CI 1.274-1.554; p < 0.001).
conclusionSerum ACSL4 levels were significantly lower in early-stage breast cancer patients and might serve as a useful serum indicator to support diagnosis. These findings suggested the potential clinical relevance of ACSL4 in breast cancer and highlighted the need for further studies to validate its diagnostic and prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.